Indicative financing overview. Prepared by GenLumina for exploratory discussions with prospective impact investors. Non-binding and subject to due diligence, corporate approvals, legal, tax and regulatory review, and definitive documentation.
Help build the next control layer in precision oncology.
Antibodies decide where — carrying our 2-nanometre medicine as their package. Light decides when. Surgeons remove the tumour; we target the residual cells that make cancer come back.
The real return is not financial: it is a chance of recovery from cancer. Every year of delay is a year patients do not get that chance.
€1 million of private capital extends our runway by two years.
Because we can match private capital with public instruments: every private euro funds more than one euro of research. Those two years give us time to find market fit — or to show early that it will not work in humans.
Enough time to finish the pre-clinical proof without having to sell under pressure.
Through existing loans, grants and research funding — this round places private capital alongside it.
If this works, in ten years it is not an alternative but state-of-the-art precision oncology.
Platform technology: partners bring the antibody, we bring the medicine.
Companies target their own cancer type with their own antibodies. We replace the drug that eliminates the cell. One link, large potential across many cancer types.
A 2-nanometre package, coupled to an antibody that finds the cancer cell itself.
The medicine stays inert until light switches it on — at the place and moment the clinician chooses.
Less recurrence, less healthy tissue removed unnecessarily. For tumours the immune system cannot reach, we are investigating intratumoral injection.
A loan, not equity. Fixed interest, one success fee.
On €100,000: €134,000 back within three years — €24,000 interest plus a €10,000 success fee. If it does not succeed you may lose your investment; the interest paid out until then is yours to keep.
- Round size
- €0.5 – 1.0 million
- Participation from
- €50,000, in steps of €25,000
- Interest
- 8% simple, paid annually in cash
- Term
- 3 years
- Repayment
- In one payment, or in three annual instalments
- Success fee
- 10% one-off, if due
- Equity and control
- None
GenLumina determines the repayment form at the end of the term, equally for all lenders. One standardised agreement with identical key terms.
This is a high-risk loan. You may lose your entire investment. GenLumina is a pre-clinical biotech company without revenue; interest, repayment and the success fee depend on future success and are not guaranteed. The loan is unsecured and non-tradable — exiting early is not possible. Only invest money you can afford to lose, and diversify. Please note: you are investing outside AFM supervision. No licence or prospectus requirement applies to this activity.
Safe, selectively taken up and effective after illumination.
Substantiate dosing, illumination and stability.
Shape programmes that can be financed per indication.
Licences, research and milestone payments.
From interest to participation
An introductory call, the full documentation, then one standardised agreement. Quarterly updates and an annual investor meeting — involved, without governance rights.
Indicative and non-binding · intended solely as a basis for exploratory discussions with prospective impact financiers · not a prospectus or investment advice · final terms subject to legal and financial review · GenLumina B.V., Leiden Bio Science Park.